Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-biota AB-21
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
H-biota AB-21 is an oral probiotic dietary supplement developed by AB-Biotics (in partnership with Kaneka and Almus Pharma) to support respiratory and immune health. The formulation consists of a patented blend of four probiotic strains—Lactiplantibacillus plantarum KABP022, KABP023, and KABP033, along with Pediococcus acidilactici KABP021—combined with Vitamin D3 (cholecalciferol). H-biota AB-21 acts via the gut-lung axis to modulate the host's immune response, enhance gut barrier function, and reduce systemic inflammation. Clinical studies have demonstrated its efficacy in accelerating recovery, reducing viral load, and shortening the duration of fever and discomfort in outpatients with mild-to-moderate COVID-19 and children with viral upper respiratory tract infections.
- Brand names
- H-biota AB-21
- Other names
- AB-21AB21AB 21H-biota ab-21Ейч-биота аб-21
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on H-biota AB-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H-biota AB-21.